RPRX · Royalty Pharma plc
$58.83
-0.19 (-0.32%)
At close · Jul 24
Market Cap
$33.88B
Shares
575.83M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
$3,000,000,000
as of 2025-01-31
Remaining Authorization
$1,700,000,000
as of 2026-03-31
Program Utilization
43.3%
$1,300,000,000 used of $3,000,000,000
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2026-03-31 YTD | $50,100,000 | 10-Q, filed 2026-05-06 |
| 2025-12-31 | $1,227,383,000 | 10-K, filed 2026-02-11 |
| 2024-12-31 | $229,651,000 | 10-K, filed 2026-02-11 |
| 2023-12-31 | $304,759,000 | 10-K, filed 2026-02-11 |
| 2022-12-31 | $0 | 10-K, filed 2025-02-12 |
| 2021-12-31 | $0 | 10-K, filed 2024-02-15 |
| 2020-12-31 | $0 | 10-K, filed 2022-02-15 |
| 2019-12-31 | $4,266,000 | 10-K, filed 2022-02-15 |
| 2018-12-31 | $0 | 10-K, filed 2021-02-24 |
Key facts
CIK
1802768
CUSIP
G7709Q104
13F (30d)
111 filings
111 filers
Visit website
Investor relations